NCT00735683

A Short-Term Study to Examine the Effects of ATHX-105 Phosphate on Weight Loss and Safety

Double-Blind, Randomized, Placebo-Controlled, 12-Week Study of the Safety and Efficacy of ATHX-105 Phosphate for the Treatment of Obesity

• Status: Withdrawn
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Healios K.K. · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

This primary purpose of this study is to determine if ATHX-105 phosphate causes weight loss over a 12-week period.

Detailed description

The rate of obesity in adults continues to increase. Obesity affects overall health and is associated with an increased risk for diabetes, high blood pressure, coronary artery disease, osteoarthritis, and sleep apnea. To date, the medication options to treat obesity have been limited. This study will examine if a new investigational drug, ATHX-105 phosphate, may cause weight loss in humans over a 12-week period.

Conditions

• Obesity

Interventions

Type	Name	Description
DRUG	ATHX-105 phosphate	includes diet, physical activity, and lifestyle modification
DRUG	Placebo	includes diet, physical activity, and lifestyle modification

Timeline

• Start date: 2008-09-01
• Primary completion: 2009-04-01
• Completion: 2009-04-01
• First posted: 2008-08-15
• Last updated: 2015-06-02